Tyvaso, a marketed PAH therapy from United Therapeutics, continued to show potential in another lung condition. Elsewhere, ...
In this video, Brian S. Kim, MD, discusses the management of patients with severe chronic spontaneous urticaria.
Connect Biopharma has reported 52-week improvements across multiple endpoints in a phase 3 trial of its eczema drug candidate, fueling the biotech’s belief that its molecule is ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 8 Best Debt Free Stocks to Buy Right Now. On March 24, 2026, ...
The treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients ...
GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.
Top-line results from the OBERON and TITANIA trials showed that tozorakimab reduced the annualised rate of moderate-to-severe ...
Sanofi and Regeneron announced that Japan’s Ministry of Health, Labour and Welfare has approved Dupixent (dupilumab) for ...
As dermatology continues to confront longstanding gaps in diagnosis and treatment across diverse populations, improving care ...
Considerable on MSN
Apogee signals best-case outlook for Dupixent rival
Apogee Therapeutics signaled a “best case scenario” on Monday for its experimental eczema treatment, ...
Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat adults with moderate-to-severe bullous pemphigoid: Paris Wednesday, March 25, 2026, 09:00 Hrs [IST] T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results